Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
AUTOR(ES)
Grandi, Tarciana, Silva, Cláudia Maria Dornelles da, Amaral, Karine Medeiros, Picon, Paulo Dornelles, Costi, Cintia, Fré, Nicole Nascimento da, Fiegenbaum, Marilu, Gregianini, Tatiana Schäffer, Niel, Christian, Rossetti, Maria Lucia Rosa
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
2014-06
RESUMO
Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs in the promoters of interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) and tumour necrosis factor (TNF) (-308 G/A, rs1800629 and -238 G/A, rs361525) genes and the outcome of PEGylated α-interferon plus ribavirin therapy were investigated. This analysis was performed in 114 Brazilian, HCV genotype 1-infected patients who had a SVR and in 85 non-responders and 64 relapsers. A significantly increased risk of having a null virological response was observed in patients carrying at least one A allele at positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) = 1.44-4.63, p = 0.001] or -238 (OR = 7.33, 95% CI = 3.59-14.93, p < 0.001) in the TNF promoter. The risk of relapsing was also elevated (-308: OR = 2.87, 95% CI = 1.51-5.44, p = 0.001; -238: OR = 4.20, 95% CI = 1.93-9.10, p < 0.001). Multiple logistic regression of TNF diplotypes showed that patients with at least two copies of the A allele had an even higher risk of having a null virological response (OR = 16.43, 95% CI = 5.70-47.34, p < 0.001) or relapsing (OR = 6.71, 95% CI = 2.18-20.66, p = 0.001). No statistically significant association was found between the other SNPs under study and anti-HCV therapy response.
Documentos Relacionados
- Polimorfismos dos genes HLA e regiões promotoras do TNF- alfa -238 e -308 como fatores de sucetibilidade a psoriase e gravidade da doença
- Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity
- What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
- Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin
- Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin